The lancet oncology
-
The lancet oncology · Jul 2022
Kerala Cancer Control Strategy 2018-30: a pragmatic vision of equitable, accessible, and affordable cancer care in low-resource settings.
The Indian state of Kerala has achieved remarkable success in communicable disease prevention and in maternal and child health. Over the past 30-40 years, non-communicable diseases, such as cancer, have emerged as new public health challenges. The Kerala Cancer Control Strategy provides a roadmap to address the various cancer-related challenges in a timely manner. The goals and targets set in the document will complement larger efforts to meet sustainable development goals. ⋯ None.
-
The lancet oncology · Jul 2022
Excess mortality in patients with cancer during the COVID-19 pandemic in Peru: an analysis of death registry data.
The COVID-19 pandemic has had a direct effect on patients with cancer, as reflected by the large number of COVID-19-related cancer deaths reported worldwide and the substantial decrease in cancer-related consultations during the pandemic. However, the impact of the COVID-19 pandemic on cancer mortality in Latin American countries has not been properly estimated. The aim of this study was to analyse the excess mortality related to cancer during the pandemic in Peru, including deaths directly or indirectly attributed to COVID-19. ⋯ International Joint Laboratories Programme of the French National Research Institute for Sustainable Development.
-
The lancet oncology · Jul 2022
Randomized Controlled TrialNivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma (median follow-up of 18·1 months). Here, we report extended follow-up of overall survival and updated efficacy and safety. ⋯ Bristol Myers Squibb and Ono Pharmaceutical.
-
The lancet oncology · Jul 2022
Meta AnalysisStereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
Patients with small-cell lung cancer (SCLC) are at high risk for intracranial metastatic disease (IMD). Although stereotactic radiosurgery (SRS) has supplanted whole brain radiotherapy (WBRT) as first-line treatment for IMD in most solid cancers, WBRT remains first-line treatment for IMD in patients with SCLC. We aimed to evaluate the efficacy of SRS in comparison with WBRT and assess treatment outcomes following SRS. ⋯ None.